QLAB Advanced Quantification Software
Philips Healthcare • Radiology • 12/20/2019
Device Purpose
The QLAB Advanced Quantification Software 13.0, particularly its 3D Auto RV feature, aims to enhance the analysis of right ventricular function from ultrasound images by integrating advanced segmentation technology and machine learning algorithms. This approach enables semi-automated, dynamic quantification of Right Ventricle volumes and ejection fraction, with non-clinical studies demonstrating its accuracy and performance relative to predicate technologies and cross-modality imaging.
Summary
The QLAB Advanced Quantification Software 13.0 is a software application package designed for viewing and quantifying image data acquired from Philips ultrasound systems. A key modification in this version is the 3D Auto RV application, which focuses on providing dynamic clinical functionality for the Right Ventricle (RV). This application achieves this by integrating the segmentation engine of the QLAB HeartModel and the TomTec-Arena 4D RV-function, employing machine learning algorithms for the automatic segmentation of the RV to identify its endocardial contours. The system offers semi-automatic 3D surface model creation, which users can subsequently review, edit, or accept to refine the quantification. The 3D Auto RV application enhances Right Ventricle quantification by combining HeartModel's auto-segmentation technology with TomTec Arena’s 4D-RV algorithm for improved RV border placement and by introducing new RV measurement parameters. Non-clinical validation studies have demonstrated its performance capabilities. Internal testing revealed that the 3D Auto RV software generates RV end-diastolic volume error rates below 15% for all tested datasets when compared to the predicate 4D RV device. Furthermore, a root mean square error (RMSE) analysis showed that, in comparison to the predicate, the 3D Auto RV measured end-diastolic RV volumes with an 8.3 ml RMSE, end-systolic RV volumes with a 2.7 ml RMSE, and RV ejection fraction with a 2.7% RMSE. An external study published in the Journal of the American Society of Echocardiography corroborated these findings, showing accurate and reproducible quantification with less than 15% difference from cardiac magnetic resonance (CMR) measurements of RV volume, and confirmed that users could effectively identify and revise contours when necessary.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the machine learning algorithm in 3D Auto RV adapt to variations in Right Ventricle morphology and image quality across different patient populations?; What specific training datasets were used for the machine learning model, and how does their diversity impact the generalizability of the 3D Auto RV application?; What is the quantitative impact on diagnostic accuracy and clinical decision-making when using the 3D Auto RV measurements compared to traditional 2D or manual 3D methods for Right Ventricle assessment?; How does the semi-automatic contour editing workflow in 3D Auto RV affect inter-observer and intra-observer variability compared to fully manual or fully automatic segmentation methods?; Beyond volume and ejection fraction, what other functional or morphological parameters of the Right Ventricle can the 3D Auto RV software accurately quantify or derive?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly